

# Global Drugs for Non-small Cell Lung Cancer Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/GB0079D5A5EEEN.html>

Date: May 2020

Pages: 150

Price: US\$ 3,900.00 (Single User License)

ID: GB0079D5A5EEEN

## Abstracts

This report focuses on the global Drugs for Non-small Cell Lung Cancer status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Drugs for Non-small Cell Lung Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Bristol-Myers Squibb

GlaxoSmithKline

Menarini

Sanofi

Ziopharm Oncology

Alchemia

Amgen

Apotex

BioMarin Pharmaceutical

CellAct Pharma

Cerulean Pharma

Cipla

Cornerstone Pharmaceuticals

Curis

CytRx

Eli Lilly

Exelixis

Fresenius Kabi

Genentech

Hikma Pharmaceuticals

Hospira

Intas Pharmaceuticals

Karyopharm Therapeutics

Kyowa Hakko Kirin

Ligand Pharmaceuticals

Market segment by Type, the product can be split into

Radiofrequency Ablation (RFA)

Radiation Therapy

Chemotherapy

Targeted Therapies

Immunotherapy

Market segment by Application, split into

Hospitals

Clinics

Other

Market segment by Regions/Countries, this report covers

North America

Europe

China

Japan

Southeast Asia

India

Central & South America

The study objectives of this report are:

To analyze global Drugs for Non-small Cell Lung Cancer status, future forecast, growth opportunity, key market and key players.

To present the Drugs for Non-small Cell Lung Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South

America.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Drugs for Non-small Cell Lung Cancer are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

## Contents

### 1 REPORT OVERVIEW

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Drugs for Non-small Cell Lung Cancer Revenue

1.4 Market Analysis by Type

1.4.1 Global Drugs for Non-small Cell Lung Cancer Market Size Growth Rate by Type: 2020 VS 2026

1.4.2 Radiofrequency Ablation (RFA)

1.4.3 Radiation Therapy

1.4.4 Chemotherapy

1.4.5 Targeted Therapies

1.4.6 Immunotherapy

1.5 Market by Application

1.5.1 Global Drugs for Non-small Cell Lung Cancer Market Share by Application: 2020 VS 2026

1.5.2 Hospitals

1.5.3 Clinics

1.5.4 Other

1.6 Study Objectives

1.7 Years Considered

### 2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Drugs for Non-small Cell Lung Cancer Market Perspective (2015-2026)

2.2 Drugs for Non-small Cell Lung Cancer Growth Trends by Regions

2.2.1 Drugs for Non-small Cell Lung Cancer Market Size by Regions: 2015 VS 2020 VS 2026

2.2.2 Drugs for Non-small Cell Lung Cancer Historic Market Share by Regions (2015-2020)

2.2.3 Drugs for Non-small Cell Lung Cancer Forecasted Market Size by Regions (2021-2026)

2.3 Industry Trends and Growth Strategy

2.3.1 Market Top Trends

2.3.2 Market Drivers

2.3.3 Market Challenges

2.3.4 Porter's Five Forces Analysis

- 2.3.5 Drugs for Non-small Cell Lung Cancer Market Growth Strategy
- 2.3.6 Primary Interviews with Key Drugs for Non-small Cell Lung Cancer Players (Opinion Leaders)

### **3 COMPETITION LANDSCAPE BY KEY PLAYERS**

- 3.1 Global Top Drugs for Non-small Cell Lung Cancer Players by Market Size
  - 3.1.1 Global Top Drugs for Non-small Cell Lung Cancer Players by Revenue (2015-2020)
  - 3.1.2 Global Drugs for Non-small Cell Lung Cancer Revenue Market Share by Players (2015-2020)
  - 3.1.3 Global Drugs for Non-small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.2 Global Drugs for Non-small Cell Lung Cancer Market Concentration Ratio
  - 3.2.1 Global Drugs for Non-small Cell Lung Cancer Market Concentration Ratio (CR5 and HHI)
  - 3.2.2 Global Top 10 and Top 5 Companies by Drugs for Non-small Cell Lung Cancer Revenue in 2019
- 3.3 Drugs for Non-small Cell Lung Cancer Key Players Head office and Area Served
- 3.4 Key Players Drugs for Non-small Cell Lung Cancer Product Solution and Service
- 3.5 Date of Enter into Drugs for Non-small Cell Lung Cancer Market
- 3.6 Mergers & Acquisitions, Expansion Plans

### **4 BREAKDOWN DATA BY TYPE (2015-2026)**

- 4.1 Global Drugs for Non-small Cell Lung Cancer Historic Market Size by Type (2015-2020)
- 4.2 Global Drugs for Non-small Cell Lung Cancer Forecasted Market Size by Type (2021-2026)

### **5 DRUGS FOR NON-SMALL CELL LUNG CANCER BREAKDOWN DATA BY APPLICATION (2015-2026)**

- 5.1 Global Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)
- 5.2 Global Drugs for Non-small Cell Lung Cancer Forecasted Market Size by Application (2021-2026)

### **6 NORTH AMERICA**

6.1 North America Drugs for Non-small Cell Lung Cancer Market Size (2015-2020)

6.2 Drugs for Non-small Cell Lung Cancer Key Players in North America (2019-2020)

6.3 North America Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020)

6.4 North America Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)

## **7 EUROPE**

7.1 Europe Drugs for Non-small Cell Lung Cancer Market Size (2015-2020)

7.2 Drugs for Non-small Cell Lung Cancer Key Players in Europe (2019-2020)

7.3 Europe Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020)

7.4 Europe Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)

## **8 CHINA**

8.1 China Drugs for Non-small Cell Lung Cancer Market Size (2015-2020)

8.2 Drugs for Non-small Cell Lung Cancer Key Players in China (2019-2020)

8.3 China Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020)

8.4 China Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)

## **9 JAPAN**

9.1 Japan Drugs for Non-small Cell Lung Cancer Market Size (2015-2020)

9.2 Drugs for Non-small Cell Lung Cancer Key Players in Japan (2019-2020)

9.3 Japan Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020)

9.4 Japan Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)

## **10 SOUTHEAST ASIA**

10.1 Southeast Asia Drugs for Non-small Cell Lung Cancer Market Size (2015-2020)

10.2 Drugs for Non-small Cell Lung Cancer Key Players in Southeast Asia (2019-2020)

10.3 Southeast Asia Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020)

10.4 Southeast Asia Drugs for Non-small Cell Lung Cancer Market Size by Application

(2015-2020)

## **11 INDIA**

- 11.1 India Drugs for Non-small Cell Lung Cancer Market Size (2015-2020)
- 11.2 Drugs for Non-small Cell Lung Cancer Key Players in India (2019-2020)
- 11.3 India Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020)
- 11.4 India Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)

## **12 CENTRAL & SOUTH AMERICA**

- 12.1 Central & South America Drugs for Non-small Cell Lung Cancer Market Size (2015-2020)
- 12.2 Drugs for Non-small Cell Lung Cancer Key Players in Central & South America (2019-2020)
- 12.3 Central & South America Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020)
- 12.4 Central & South America Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020)

## **13 KEY PLAYERS PROFILES**

- 13.1 Bristol-Myers Squibb
  - 13.1.1 Bristol-Myers Squibb Company Details
  - 13.1.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
  - 13.1.3 Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Introduction
  - 13.1.4 Bristol-Myers Squibb Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020))
  - 13.1.5 Bristol-Myers Squibb Recent Development
- 13.2 GlaxoSmithKline
  - 13.2.1 GlaxoSmithKline Company Details
  - 13.2.2 GlaxoSmithKline Business Overview and Its Total Revenue
  - 13.2.3 GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Introduction
  - 13.2.4 GlaxoSmithKline Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  - 13.2.5 GlaxoSmithKline Recent Development
- 13.3 Menarini
  - 13.3.1 Menarini Company Details



- 13.3.2 Menarini Business Overview and Its Total Revenue
- 13.3.3 Menarini Drugs for Non-small Cell Lung Cancer Introduction
- 13.3.4 Menarini Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
- 13.3.5 Menarini Recent Development
- 13.4 Sanofi
  - 13.4.1 Sanofi Company Details
  - 13.4.2 Sanofi Business Overview and Its Total Revenue
  - 13.4.3 Sanofi Drugs for Non-small Cell Lung Cancer Introduction
  - 13.4.4 Sanofi Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  - 13.4.5 Sanofi Recent Development
- 13.5 Ziopharm Oncology
  - 13.5.1 Ziopharm Oncology Company Details
  - 13.5.2 Ziopharm Oncology Business Overview and Its Total Revenue
  - 13.5.3 Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Introduction
  - 13.5.4 Ziopharm Oncology Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  - 13.5.5 Ziopharm Oncology Recent Development
- 13.6 Alchemia
  - 13.6.1 Alchemia Company Details
  - 13.6.2 Alchemia Business Overview and Its Total Revenue
  - 13.6.3 Alchemia Drugs for Non-small Cell Lung Cancer Introduction
  - 13.6.4 Alchemia Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  - 13.6.5 Alchemia Recent Development
- 13.7 Amgen
  - 13.7.1 Amgen Company Details
  - 13.7.2 Amgen Business Overview and Its Total Revenue
  - 13.7.3 Amgen Drugs for Non-small Cell Lung Cancer Introduction
  - 13.7.4 Amgen Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  - 13.7.5 Amgen Recent Development
- 13.8 Apotex
  - 13.8.1 Apotex Company Details
  - 13.8.2 Apotex Business Overview and Its Total Revenue
  - 13.8.3 Apotex Drugs for Non-small Cell Lung Cancer Introduction
  - 13.8.4 Apotex Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)

- 13.8.5 Apotex Recent Development
- 13.9 BioMarin Pharmaceutical
  - 13.9.1 BioMarin Pharmaceutical Company Details
  - 13.9.2 BioMarin Pharmaceutical Business Overview and Its Total Revenue
  - 13.9.3 BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Introduction
  - 13.9.4 BioMarin Pharmaceutical Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  - 13.9.5 BioMarin Pharmaceutical Recent Development
- 13.10 CellAct Pharma
  - 13.10.1 CellAct Pharma Company Details
  - 13.10.2 CellAct Pharma Business Overview and Its Total Revenue
  - 13.10.3 CellAct Pharma Drugs for Non-small Cell Lung Cancer Introduction
  - 13.10.4 CellAct Pharma Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  - 13.10.5 CellAct Pharma Recent Development
- 13.11 Cerulean Pharma
  - 10.11.1 Cerulean Pharma Company Details
  - 10.11.2 Cerulean Pharma Business Overview and Its Total Revenue
  - 10.11.3 Cerulean Pharma Drugs for Non-small Cell Lung Cancer Introduction
  - 10.11.4 Cerulean Pharma Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  - 10.11.5 Cerulean Pharma Recent Development
- 13.12 Cipla
  - 10.12.1 Cipla Company Details
  - 10.12.2 Cipla Business Overview and Its Total Revenue
  - 10.12.3 Cipla Drugs for Non-small Cell Lung Cancer Introduction
  - 10.12.4 Cipla Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  - 10.12.5 Cipla Recent Development
- 13.13 Cornerstone Pharmaceuticals
  - 10.13.1 Cornerstone Pharmaceuticals Company Details
  - 10.13.2 Cornerstone Pharmaceuticals Business Overview and Its Total Revenue
  - 10.13.3 Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Introduction
  - 10.13.4 Cornerstone Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  - 10.13.5 Cornerstone Pharmaceuticals Recent Development
- 13.14 Curis
  - 10.14.1 Curis Company Details

- 10.14.2 Curis Business Overview and Its Total Revenue
- 10.14.3 Curis Drugs for Non-small Cell Lung Cancer Introduction
- 10.14.4 Curis Revenue in Drugs for Non-small Cell Lung Cancer Business  
(2015-2020)
- 10.14.5 Curis Recent Development
- 13.15 CytRx
  - 10.15.1 CytRx Company Details
  - 10.15.2 CytRx Business Overview and Its Total Revenue
  - 10.15.3 CytRx Drugs for Non-small Cell Lung Cancer Introduction
  - 10.15.4 CytRx Revenue in Drugs for Non-small Cell Lung Cancer Business  
(2015-2020)
  - 10.15.5 CytRx Recent Development
- 13.16 Eli Lilly
  - 10.16.1 Eli Lilly Company Details
  - 10.16.2 Eli Lilly Business Overview and Its Total Revenue
  - 10.16.3 Eli Lilly Drugs for Non-small Cell Lung Cancer Introduction
  - 10.16.4 Eli Lilly Revenue in Drugs for Non-small Cell Lung Cancer Business  
(2015-2020)
  - 10.16.5 Eli Lilly Recent Development
- 13.17 Exelixis
  - 10.17.1 Exelixis Company Details
  - 10.17.2 Exelixis Business Overview and Its Total Revenue
  - 10.17.3 Exelixis Drugs for Non-small Cell Lung Cancer Introduction
  - 10.17.4 Exelixis Revenue in Drugs for Non-small Cell Lung Cancer Business  
(2015-2020)
  - 10.17.5 Exelixis Recent Development
- 13.18 Fresenius Kabi
  - 10.18.1 Fresenius Kabi Company Details
  - 10.18.2 Fresenius Kabi Business Overview and Its Total Revenue
  - 10.18.3 Fresenius Kabi Drugs for Non-small Cell Lung Cancer Introduction
  - 10.18.4 Fresenius Kabi Revenue in Drugs for Non-small Cell Lung Cancer Business  
(2015-2020)
  - 10.18.5 Fresenius Kabi Recent Development
- 13.19 Genentech
  - 10.19.1 Genentech Company Details
  - 10.19.2 Genentech Business Overview and Its Total Revenue
  - 10.19.3 Genentech Drugs for Non-small Cell Lung Cancer Introduction
  - 10.19.4 Genentech Revenue in Drugs for Non-small Cell Lung Cancer Business  
(2015-2020)

- 10.19.5 Genentech Recent Development
- 13.20 Hikma Pharmaceuticals
  - 10.20.1 Hikma Pharmaceuticals Company Details
  - 10.20.2 Hikma Pharmaceuticals Business Overview and Its Total Revenue
  - 10.20.3 Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Introduction
  - 10.20.4 Hikma Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  - 10.20.5 Hikma Pharmaceuticals Recent Development
- 13.21 Hospira
  - 10.21.1 Hospira Company Details
  - 10.21.2 Hospira Business Overview and Its Total Revenue
  - 10.21.3 Hospira Drugs for Non-small Cell Lung Cancer Introduction
  - 10.21.4 Hospira Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  - 10.21.5 Hospira Recent Development
- 13.22 Intas Pharmaceuticals
  - 10.22.1 Intas Pharmaceuticals Company Details
  - 10.22.2 Intas Pharmaceuticals Business Overview and Its Total Revenue
  - 10.22.3 Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Introduction
  - 10.22.4 Intas Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  - 10.22.5 Intas Pharmaceuticals Recent Development
- 13.23 Karyopharm Therapeutics
  - 10.23.1 Karyopharm Therapeutics Company Details
  - 10.23.2 Karyopharm Therapeutics Business Overview and Its Total Revenue
  - 10.23.3 Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Introduction
  - 10.23.4 Karyopharm Therapeutics Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  - 10.23.5 Karyopharm Therapeutics Recent Development
- 13.24 Kyowa Hakko Kirin
  - 10.24.1 Kyowa Hakko Kirin Company Details
  - 10.24.2 Kyowa Hakko Kirin Business Overview and Its Total Revenue
  - 10.24.3 Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Introduction
  - 10.24.4 Kyowa Hakko Kirin Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
  - 10.24.5 Kyowa Hakko Kirin Recent Development
- 13.25 Ligand Pharmaceuticals
  - 10.25.1 Ligand Pharmaceuticals Company Details
  - 10.25.2 Ligand Pharmaceuticals Business Overview and Its Total Revenue

- 10.25.3 Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Introduction
- 10.25.4 Ligand Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020)
- 10.25.5 Ligand Pharmaceuticals Recent Development

## **14 ANALYST'S VIEWPOINTS/CONCLUSIONS**

## **15 APPENDIX**

- 15.1 Research Methodology
  - 15.1.1 Methodology/Research Approach
  - 15.1.2 Data Source
- 15.2 Disclaimer
- 15.3 Author Details

## List Of Tables

### LIST OF TABLES

Table 1. Drugs for Non-small Cell Lung Cancer Key Market Segments

Table 2. Key Players Covered: Ranking by Drugs for Non-small Cell Lung Cancer Revenue

Table 3. Ranking of Global Top Drugs for Non-small Cell Lung Cancer Manufacturers by Revenue (US\$ Million) in 2019

Table 4. Global Drugs for Non-small Cell Lung Cancer Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026

Table 5. Key Players of Radiofrequency Ablation (RFA)

Table 6. Key Players of Radiation Therapy

Table 7. Key Players of Chemotherapy

Table 8. Key Players of Targeted Therapies

Table 9. Key Players of Immunotherapy

Table 10. Global Drugs for Non-small Cell Lung Cancer Market Size Growth by Application (US\$ Million): 2020 VS 2026

Table 11. Global Drugs for Non-small Cell Lung Cancer Market Size by Regions (US\$ Million): 2020 VS 2026

Table 12. Global Drugs for Non-small Cell Lung Cancer Market Size by Regions (2015-2020) (US\$ Million)

Table 13. Global Drugs for Non-small Cell Lung Cancer Market Share by Regions (2015-2020)

Table 14. Global Drugs for Non-small Cell Lung Cancer Forecasted Market Size by Regions (2021-2026) (US\$ Million)

Table 15. Global Drugs for Non-small Cell Lung Cancer Market Share by Regions (2021-2026)

Table 16. Market Top Trends

Table 17. Key Drivers: Impact Analysis

Table 18. Key Challenges

Table 19. Drugs for Non-small Cell Lung Cancer Market Growth Strategy

Table 20. Main Points Interviewed from Key Drugs for Non-small Cell Lung Cancer Players

Table 21. Global Drugs for Non-small Cell Lung Cancer Revenue by Players (2015-2020) (Million US\$)

Table 22. Global Drugs for Non-small Cell Lung Cancer Market Share by Players (2015-2020)

Table 23. Global Top Drugs for Non-small Cell Lung Cancer Players by Company Type

(Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Non-small Cell Lung Cancer as of 2019)

Table 24. Global Drugs for Non-small Cell Lung Cancer by Players Market Concentration Ratio (CR5 and HHI)

Table 25. Key Players Headquarters and Area Served

Table 26. Key Players Drugs for Non-small Cell Lung Cancer Product Solution and Service

Table 27. Date of Enter into Drugs for Non-small Cell Lung Cancer Market

Table 28. Mergers & Acquisitions, Expansion Plans

Table 29. Global Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020) (Million US\$)

Table 30. Global Drugs for Non-small Cell Lung Cancer Market Size Share by Type (2015-2020)

Table 31. Global Drugs for Non-small Cell Lung Cancer Revenue Market Share by Type (2021-2026)

Table 32. Global Drugs for Non-small Cell Lung Cancer Market Size Share by Application (2015-2020)

Table 33. Global Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020) (Million US\$)

Table 34. Global Drugs for Non-small Cell Lung Cancer Market Size Share by Application (2021-2026)

Table 35. North America Key Players Drugs for Non-small Cell Lung Cancer Revenue (2019-2020) (Million US\$)

Table 36. North America Key Players Drugs for Non-small Cell Lung Cancer Market Share (2019-2020)

Table 37. North America Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020) (Million US\$)

Table 38. North America Drugs for Non-small Cell Lung Cancer Market Share by Type (2015-2020)

Table 39. North America Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020) (Million US\$)

Table 40. North America Drugs for Non-small Cell Lung Cancer Market Share by Application (2015-2020)

Table 41. Europe Key Players Drugs for Non-small Cell Lung Cancer Revenue (2019-2020) (Million US\$)

Table 42. Europe Key Players Drugs for Non-small Cell Lung Cancer Market Share (2019-2020)

Table 43. Europe Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020) (Million US\$)



Table 44. Europe Drugs for Non-small Cell Lung Cancer Market Share by Type (2015-2020)

Table 45. Europe Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020) (Million US\$)

Table 46. Europe Drugs for Non-small Cell Lung Cancer Market Share by Application (2015-2020)

Table 47. China Key Players Drugs for Non-small Cell Lung Cancer Revenue (2019-2020) (Million US\$)

Table 48. China Key Players Drugs for Non-small Cell Lung Cancer Market Share (2019-2020)

Table 49. China Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020) (Million US\$)

Table 50. China Drugs for Non-small Cell Lung Cancer Market Share by Type (2015-2020)

Table 51. China Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020) (Million US\$)

Table 52. China Drugs for Non-small Cell Lung Cancer Market Share by Application (2015-2020)

Table 53. Japan Key Players Drugs for Non-small Cell Lung Cancer Revenue (2019-2020) (Million US\$)

Table 54. Japan Key Players Drugs for Non-small Cell Lung Cancer Market Share (2019-2020)

Table 55. Japan Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020) (Million US\$)

Table 56. Japan Drugs for Non-small Cell Lung Cancer Market Share by Type (2015-2020)

Table 57. Japan Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020) (Million US\$)

Table 58. Japan Drugs for Non-small Cell Lung Cancer Market Share by Application (2015-2020)

Table 59. Southeast Asia Key Players Drugs for Non-small Cell Lung Cancer Revenue (2019-2020) (Million US\$)

Table 60. Southeast Asia Key Players Drugs for Non-small Cell Lung Cancer Market Share (2019-2020)

Table 61. Southeast Asia Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020) (Million US\$)

Table 62. Southeast Asia Drugs for Non-small Cell Lung Cancer Market Share by Type (2015-2020)

Table 63. Southeast Asia Drugs for Non-small Cell Lung Cancer Market Size by



Application (2015-2020) (Million US\$)

Table 64. Southeast Asia Drugs for Non-small Cell Lung Cancer Market Share by Application (2015-2020)

Table 65. India Key Players Drugs for Non-small Cell Lung Cancer Revenue (2019-2020) (Million US\$)

Table 66. India Key Players Drugs for Non-small Cell Lung Cancer Market Share (2019-2020)

Table 67. India Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020) (Million US\$)

Table 68. India Drugs for Non-small Cell Lung Cancer Market Share by Type (2015-2020)

Table 69. India Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020) (Million US\$)

Table 70. India Drugs for Non-small Cell Lung Cancer Market Share by Application (2015-2020)

Table 71. Central & South America Key Players Drugs for Non-small Cell Lung Cancer Revenue (2019-2020) (Million US\$)

Table 72. Central & South America Key Players Drugs for Non-small Cell Lung Cancer Market Share (2019-2020)

Table 73. Central & South America Drugs for Non-small Cell Lung Cancer Market Size by Type (2015-2020) (Million US\$)

Table 74. Central & South America Drugs for Non-small Cell Lung Cancer Market Share by Type (2015-2020)

Table 75. Central & South America Drugs for Non-small Cell Lung Cancer Market Size by Application (2015-2020) (Million US\$)

Table 76. Central & South America Drugs for Non-small Cell Lung Cancer Market Share by Application (2015-2020)

Table 77. Bristol-Myers Squibb Company Details

Table 78. Bristol-Myers Squibb Business Overview

Table 79. Bristol-Myers Squibb Product

Table 80. Bristol-Myers Squibb Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)

Table 81. Bristol-Myers Squibb Recent Development

Table 82. GlaxoSmithKline Company Details

Table 83. GlaxoSmithKline Business Overview

Table 84. GlaxoSmithKline Product

Table 85. GlaxoSmithKline Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)

Table 86. GlaxoSmithKline Recent Development

- Table 87. Menarini Company Details
- Table 88. Menarini Business Overview
- Table 89. Menarini Product
- Table 90. Menarini Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)
- Table 91. Menarini Recent Development
- Table 92. Sanofi Company Details
- Table 93. Sanofi Business Overview
- Table 94. Sanofi Product
- Table 95. Sanofi Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)
- Table 96. Sanofi Recent Development
- Table 97. Ziopharm Oncology Company Details
- Table 98. Ziopharm Oncology Business Overview
- Table 99. Ziopharm Oncology Product
- Table 100. Ziopharm Oncology Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)
- Table 101. Ziopharm Oncology Recent Development
- Table 102. Alchemia Company Details
- Table 103. Alchemia Business Overview
- Table 104. Alchemia Product
- Table 105. Alchemia Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)
- Table 106. Alchemia Recent Development
- Table 107. Amgen Company Details
- Table 108. Amgen Business Overview
- Table 109. Amgen Product
- Table 110. Amgen Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)
- Table 111. Amgen Recent Development
- Table 112. Apotex Business Overview
- Table 113. Apotex Product
- Table 114. Apotex Company Details
- Table 115. Apotex Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)
- Table 116. Apotex Recent Development
- Table 117. BioMarin Pharmaceutical Company Details
- Table 118. BioMarin Pharmaceutical Business Overview
- Table 119. BioMarin Pharmaceutical Product

Table 120. BioMarin Pharmaceutical Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)

Table 121. BioMarin Pharmaceutical Recent Development

Table 122. CellAct Pharma Company Details

Table 123. CellAct Pharma Business Overview

Table 124. CellAct Pharma Product

Table 125. CellAct Pharma Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)

Table 126. CellAct Pharma Recent Development

Table 127. Cerulean Pharma Company Details

Table 128. Cerulean Pharma Business Overview

Table 129. Cerulean Pharma Product

Table 130. Cerulean Pharma Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)

Table 131. Cerulean Pharma Recent Development

Table 132. Cipla Company Details

Table 133. Cipla Business Overview

Table 134. Cipla Product

Table 135. Cipla Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)

Table 136. Cipla Recent Development

Table 137. Cornerstone Pharmaceuticals Company Details

Table 138. Cornerstone Pharmaceuticals Business Overview

Table 139. Cornerstone Pharmaceuticals Product

Table 140. Cornerstone Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)

Table 141. Cornerstone Pharmaceuticals Recent Development

Table 142. Curis Company Details

Table 143. Curis Business Overview

Table 144. Curis Product

Table 145. Curis Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)

Table 146. Curis Recent Development

Table 147. CytRx Company Details

Table 148. CytRx Business Overview

Table 149. CytRx Product

Table 150. CytRx Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)

Table 151. CytRx Recent Development

- Table 152. Eli Lilly Company Details
- Table 153. Eli Lilly Business Overview
- Table 154. Eli Lilly Product
- Table 155. Eli Lilly Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)
- Table 156. Eli Lilly Recent Development
- Table 157. Exelixis Company Details
- Table 158. Exelixis Business Overview
- Table 159. Exelixis Product
- Table 160. Exelixis Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)
- Table 161. Exelixis Recent Development
- Table 162. Fresenius Kabi Company Details
- Table 163. Fresenius Kabi Business Overview
- Table 164. Fresenius Kabi Product
- Table 165. Fresenius Kabi Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)
- Table 166. Fresenius Kabi Recent Development
- Table 167. Genentech Company Details
- Table 168. Genentech Business Overview
- Table 169. Genentech Product
- Table 170. Genentech Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)
- Table 171. Genentech Recent Development
- Table 172. Hikma Pharmaceuticals Company Details
- Table 173. Hikma Pharmaceuticals Business Overview
- Table 174. Hikma Pharmaceuticals Product
- Table 175. Hikma Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)
- Table 176. Hikma Pharmaceuticals Recent Development
- Table 177. Hospira Company Details
- Table 178. Hospira Business Overview
- Table 179. Hospira Product
- Table 180. Hospira Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)
- Table 181. Hospira Recent Development
- Table 182. Intas Pharmaceuticals Company Details
- Table 183. Intas Pharmaceuticals Business Overview
- Table 184. Intas Pharmaceuticals Product

Table 185. Intas Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)

Table 186. Intas Pharmaceuticals Recent Development

Table 187. Karyopharm Therapeutics Company Details

Table 188. Karyopharm Therapeutics Business Overview

Table 189. Karyopharm Therapeutics Product

Table 190. Karyopharm Therapeutics Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)

Table 191. Karyopharm Therapeutics Recent Development

Table 192. Kyowa Hakko Kirin Company Details

Table 193. Kyowa Hakko Kirin Business Overview

Table 194. Kyowa Hakko Kirin Product

Table 195. Kyowa Hakko Kirin Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)

Table 196. Kyowa Hakko Kirin Recent Development

Table 197. Ligand Pharmaceuticals Company Details

Table 198. Ligand Pharmaceuticals Business Overview

Table 199. Ligand Pharmaceuticals Product

Table 200. Ligand Pharmaceuticals Revenue in Drugs for Non-small Cell Lung Cancer Business (2015-2020) (Million US\$)

Table 201. Ligand Pharmaceuticals Recent Development

Table 202. Research Programs/Design for This Report

Table 203. Key Data Information from Secondary Sources

Table 204. Key Data Information from Primary Sources

## List Of Figures

### LIST OF FIGURES

Figure 1. Global Drugs for Non-small Cell Lung Cancer Market Share by Type: 2020 VS 2026

Figure 2. Radiofrequency Ablation (RFA) Features

Figure 3. Radiation Therapy Features

Figure 4. Chemotherapy Features

Figure 5. Targeted Therapies Features

Figure 6. Immunotherapy Features

Figure 7. Global Drugs for Non-small Cell Lung Cancer Market Share by Application: 2020 VS 2026

Figure 8. Hospitals Case Studies

Figure 9. Clinics Case Studies

Figure 10. Other Case Studies

Figure 11. Drugs for Non-small Cell Lung Cancer Report Years Considered

Figure 12. Global Drugs for Non-small Cell Lung Cancer Market Size YoY Growth 2015-2026 (US\$ Million)

Figure 13. Global Drugs for Non-small Cell Lung Cancer Market Share by Regions: 2020 VS 2026

Figure 14. Global Drugs for Non-small Cell Lung Cancer Market Share by Regions (2021-2026)

Figure 15. Porter's Five Forces Analysis

Figure 16. Global Drugs for Non-small Cell Lung Cancer Market Share by Players in 2019

Figure 17. Global Top Drugs for Non-small Cell Lung Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Non-small Cell Lung Cancer as of 2019)

Figure 18. The Top 10 and 5 Players Market Share by Drugs for Non-small Cell Lung Cancer Revenue in 2019

Figure 19. North America Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2015-2020) (Million US\$)

Figure 20. Europe Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2015-2020) (Million US\$)

Figure 21. China Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2015-2020) (Million US\$)

Figure 22. Japan Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2015-2020) (Million US\$)



Figure 23. Southeast Asia Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2015-2020) (Million US\$)

Figure 24. India Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2015-2020) (Million US\$)

Figure 25. Central & South America Drugs for Non-small Cell Lung Cancer Market Size YoY Growth (2015-2020) (Million US\$)

Figure 26. Bristol-Myers Squibb Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 27. Bristol-Myers Squibb Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)

Figure 28. GlaxoSmithKline Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 29. GlaxoSmithKline Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)

Figure 30. Menarini Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 31. Menarini Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)

Figure 32. Sanofi Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 33. Sanofi Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)

Figure 34. Ziopharm Oncology Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 35. Ziopharm Oncology Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)

Figure 36. Alchemia Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 37. Alchemia Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)

Figure 38. Amgen Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 39. Amgen Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)

Figure 40. Apotex Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 41. Apotex Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)

Figure 42. BioMarin Pharmaceutical Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 43. BioMarin Pharmaceutical Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)

Figure 44. CellAct Pharma Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 45. CellAct Pharma Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)

Figure 46. Cerulean Pharma Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 47. Cerulean Pharma Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)

Figure 48. Cipla Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 49. Cipla Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)

Figure 50. Cornerstone Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 51. Cornerstone Pharmaceuticals Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)

Figure 52. Curis Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 53. Curis Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)

Figure 54. CytRx Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 55. CytRx Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)

Figure 56. Eli Lilly Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 57. Eli Lilly Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)

Figure 58. Exelixis Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 59. Exelixis Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)

Figure 60. Fresenius Kabi Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 61. Fresenius Kabi Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)

Figure 62. Genentech Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 63. Genentech Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)

Figure 64. Hikma Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 65. Hikma Pharmaceuticals Revenue Growth Rate in Drugs for Non-small Cell Lung Cancer Business (2015-2020)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed



## I would like to order

Product name: Global Drugs for Non-small Cell Lung Cancer Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/GB0079D5A5EEEN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB0079D5A5EEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

